INSUBCONTINENT EXCLUSIVE:
For this quarter, global API sales reached Rs 362.2 crore, marking a 40.3 per cent increase from Q4 FY24
IST
Mumbai-headquartered Lupin posted a 77.2 per cent year-on-year (Y-o-Y) increase in profit after tax (PAT) during the first quarter of
the financial year FY25, ending on June 30, reaching Rs 801 crore
This increase in PAT was attributed to new product launches and strong performance in key geographies.
On a sequential basis, the company
exhibited a significant 122.9 per cent increase in PAT, with revenue also increasing by 12.6 per cent
The Ebitda (earnings before interest, tax, depreciation, and amortisation) margin rose by 48.9 per cent Y-o-Y, reaching Rs 1,308.8
momentum we built through FY24, with performance driven by new products, key geographies, and improvement in our operating margin and
We are on track for strong, sustainable growth and margin improvement backed by growth in sales, commercial and operating efficiencies, and
expenditure of Rs 111.7 crore for the quarter
Notably, the company held a net debt position of Rs 195 million and a net debt-to-equity ratio of 0.00, indicating a strong financial
position with more cash than liabilities.
In Q1 FY25, North America sales totalled Rs 2,040.8 crore, reflecting a 7.4 per cent increase
from Rs 1,900.6 crore in Q4 FY24 and a 28.3 per cent rise from Rs 1,590.5 crore in Q1 FY24
During the quarter, the company received 6 ANDA approvals from the US FDA and launched 3 new products
Lupin now offers 161 generic products in the US and maintains its position as the 3rd largest pharmaceutical player in both the US generics
market and the total US market by prescriptions (IQVIA Qtr
Lupin leads in 50 of its marketed generics in the US and is among the top 3 in 103 of its marketed products (IQVIA Qtr
June 2024).
For Q1 FY25, India formulation sales reached Rs 1,925.9 crore, marking a 20.3 per cent increase from Rs 1,601.5 crore in Q4
The company launched 3 new brands across Cardio, Neuro/CNS, and GI therapies during the quarter
Lupin is ranked as the 7th largest company in the Indian pharmaceutical market (IQVIA MAT June 2024).
Europe, Middle East, and Africa
In South Africa, Q1 FY25 sales amounted to ZAR 337 million, compared to ZAR 438 million in Q4 FY24 and ZAR 295 million in Q1 FY24
reached Rs 362.2 crore, marking a 40.3 per cent increase from Q4 FY24
development (R-D) for the quarter
Lupin received 6 ANDA approvals from the US FDA during the quarter
As of June 30, 2024, Lupin has submitted a total of 430 ANDA filings to the US FDA, with 325 approvals granted
The company now has 50 First-to-File (FTF) filings, including 17 exclusive FTF opportunities, and cumulative US DMF filings stand at 157 as
of June 30, 2024.First Published: Aug 07 2024 | 7:53 AMIST
